Clinical trials: Advanced RCC
Neoplasms
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors
The purpose of this study is to determine the recommended phase 2 dose (RP2D) regimen(s) of JNJ-78306358 in Part 1 (Dose Escalation) and to determine the safety of JNJ-78306358 at the RP2D regimen(s) in Part 2 (Dose Expansion).
- Trial name
- NCT04991740
- Testing
- JNJ-78306358
- Where
- 5 sites in Israel, Spain
- Volunteers
- 39 people
- Sponsor
- Janssen Research & Development, LLC
Neoplasms
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00264433
- Testing
- ADH -1 (Exherin™)
- Where
- 11 sites in United States, Canada
- Sponsor
- Adherex Technologies, Inc.
Advanced Renal Cancer
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.
- Trial name
- NCT04523272
- Testing
- TQB2450, Anlotinib, Sunitinib
- Where
- 39 sites in China
- Volunteers
- 528 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Renal Cell Carcinoma, Non-hodgkin's Lymphoma
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
The purpose of this study is to determine if MDX-1203 is safe for the treatment of renal cell carcinoma or non-hodgkin's lymphoma.
- Trial name
- NCT00944905
- Testing
- MDX-1203
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Select Advanced Malignancies, Kidney Cancer
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
To evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Participants with Select Advanced Malignancies.
- Conditions
- Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma
- Trial name
- NCT02118337
- Testing
- MEDI0680, Durvalumab, Nivolumab
- Where
- 27 sites in United States, Australia and 4 more
- Volunteers
- 97 people
- Sponsor
- MedImmune LLC
Renal Cell Carcinoma
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.
- Trial name
- NCT04088500
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in United States, Canada
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Advanced Renal Cell Carcinoma
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma
The purpose of this study is to evaluate the efficacy of cabozantinib measured by Independent Radiology Committee (IRC)-assessed objective response rate (ORR) in Japanese participants with advanced renal cell carcinoma (RCC) that…
- Trial name
- NCT03339219
- Testing
- Cabozantinib
- Where
- 19 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Takeda
Advanced Solid Tumor
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
- Trial name
- NCT04349267
- Testing
- BMS-986315, nivolumab, cetuximab
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Adult, Metastatic Solid Tumor
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab…
- Conditions
- Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer
- Trial name
- NCT05856981
- Testing
- ADU-1805, Pembrolizumab
- Where
- 11 sites in United States, Belgium and 1 more
- Volunteers
- 130 people
- Sponsor
- Sairopa B.V.
Renal Cell Carcinoma
Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma
The objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (RCC) following prior VEGF-targeted therapy in real life settings in terms of dose modifications due to…
- Trial name
- CASSIOPE (NCT03419572)
- Testing
- Data collection
- Where
- 91 sites in Austria, Belgium and 9 more
- Volunteers
- 689 people
- Sponsor
- Ipsen
Renal Cell Carcinoma, First-line Treatment
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
This is a Phase II, open-label trial to evaluate the efficacy and safety of AK104 monotherapy or AK104 in combination with axitinib as a first-line treatment for advanced/metastatic renal cell carcinoma (RCC).
- Trial name
- NCT05256472
- Testing
- AK104, axitinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Akeso
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the…
- Trial name
- NCT07011719
- Testing
- Casdatifan, Cabozantinib
- Where
- 191 sites in United States, Argentina and 15 more
- Volunteers
- 720 people
- Sponsor
- Arcus Biosciences, Inc.
Renal Cell Carcinoma
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment…
- Trial name
- LITESPARK-033 (NCT07227402)
- Testing
- Belzutifan, Zanzalintinib, Cabozantinib
- Where
- 127 sites in United States, Argentina and 21 more
- Volunteers
- 904 people
- Sponsor
- Merck Sharp & Dohme LLC
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Solid Tumor, Microsatellite Stable Colorectal Cancer
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).
- Conditions
- Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- RAPTOR (NCT04301011)
- Testing
- TBio-6517, Pembrolizumab
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 27 people
- Sponsor
- Turnstone Biologics, Corp.
Renal Cell Carcinoma
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
This is an open-label, single arm, multicenter study. Subjects will be stratified by histology (clear cell versus non-clear cell). Enrollment of non-clear cell subjects will be limited to ≤ 30% of the entire study population.
- Trial name
- NCT01297244
- Testing
- Tivozanib
- Where
- 25 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Advanced Solid Tumors
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
This is an extension study that will allow participants to continue to receive study therapy when the original studies into which they were enrolled have reached their designated end-dates.
- Trial name
- NCT01178411
- Testing
- Tivantinib, Anti-Cancer Combination Therapy
- Volunteers
- 60 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Hepato Cellular Carcinoma (HCC), Renal Cell Cancer
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301…
- Trial name
- NCT07494435
- Testing
- WGI-0301, Nivolumab (240 mg)
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
Renal Cell Carcinoma
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Despite substantial improvements of patients outcome in advanced RCC, durable and complete response is uncommon. The majority of patients eventually develop resistance and exhibit disease progression.
- Trial name
- NCT02133742
- Testing
- Axitinib, MK-3475
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Pfizer
Kidney Neoplasms
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
The purpose of this study is to assess the safety and efficacy of nivolumab combined with ipilimumab in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC) or metastatic RCC…
- Trial name
- CheckMate 7C9 (NCT04513522)
- Testing
- Nivolumab, Ipilimumab
- Where
- 11 sites in India
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb